Biogen Traders Poised for FDA Verdict on Alzheimer’s Treatment

This post was originally published on this site

[unable to retrieve full-text content]Investors are getting emboldened with Biogen Inc. shares climbing more than 9% over the last four sessions ahead of a regulatory decision on the biotech company’s Alzheimer’s disease medicine. The …